Tafinlar (dabrafenib) — Medica
Histiocytic Neoplasm (Langerhans cell histiocytosis or Erdheim-Chester disease)
Initial criteria
- Patient has Langerhans cell histiocytosis OR Erdheim-Chester disease
- Patient has BRAF V600 mutation-positive disease
Approval duration
1 year